Abbott Laboratories (NYSE: ABT) reported Q1 ongoing EPS of $0.41, $0.05 better than the analyst estimate of $0.36. Revenue for the quarter came in at $5.24 billion versus the consensus estimate of $5.29 billion.

Abbott reaffirmed FY2014 guidance.

For earnings history and earnings-related data on Abbott Laboratories (ABT) click here.